Praluent (Alirocumab) Cost in South Dakota 2026

What Does Praluent Actually Cost in South Dakota Right Now?

Brand-name Praluent has a manufacturer list price near $580 per month at South Dakota retail pharmacies in 2026. That figure applies to the 75 mg and 150 mg prefilled pen formulations dispensed every two weeks. Without insurance or a savings program, most South Dakota patients pay close to that full amount out of pocket.

Praluent belongs to the PCSK9 inhibitor class, which works by blocking the PCSK9 protein and allowing the liver to clear more LDL cholesterol from the bloodstream. The FDA approved alirocumab in August 2015 initially for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need additional LDL lowering on top of maximally tolerated statin therapy. That indication was expanded in July 2018 to include reducing the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, based directly on ODYSSEY OUTCOMES data [1].

The list price has remained relatively stable since Regeneron and Sanofi cut it by 60% in 2019, dropping from roughly $14,000 per year to approximately $6,500 to $7,000 per year. That reduction was a direct response to payer pressure and the arrival of evolocumab (Repatha) competition. Even at the reduced price, $580 per month is a significant burden for uninsured or underinsured South Dakota residents, particularly in rural communities where wage levels and employer benefit packages may be more limited. The state's median household income sits near $65,000 per year, meaning a full-price Praluent course would consume roughly 11% of pre-tax income for a median earner paying entirely out of pocket.

South Dakota has 21 retail pharmacy chains and independent locations in its larger metro areas (Sioux Falls, Rapid City, Aberdeen), but pricing does not vary materially across dispensers for a single-source brand drug. Goodrx and similar aggregators show cash prices within $10 to $30 of the manufacturer WAC in SD zip codes sampled in early 2026.

South Dakota Medicaid and Praluent: The Current Coverage Picture

South Dakota Medicaid does not cover Praluent as of January 2026. This is consistent with the coverage posture many state Medicaid programs adopted after initial PCSK9 approval, citing cost-effectiveness thresholds that exceed typical Medicaid formulary benchmarks.

The Institute for Clinical and Economic Review (ICER) 2022 update on PCSK9 inhibitors concluded that at prices above approximately $4,500 per year, alirocumab and evolocumab fall outside commonly accepted cost-effectiveness thresholds of $100,000 to $150,000 per quality-adjusted life year (QALY) for patients with HeFH, though ICER noted the calculus shifts favorably for high-risk post-acute coronary syndrome (ACS) patients [2]. South Dakota's Medicaid Drug Utilization Review (DUR) Board references ICER analyses alongside CMS guidance when setting formulary policy, and the current result is a non-covered status for alirocumab.

Patients enrolled in South Dakota Medicaid who have a documented diagnosis of HeFH or who experienced a recent ACS event should ask their cardiologist or primary care provider to submit a coverage exception request. Exception approval rates for PCSK9 inhibitors under Medicaid exception processes vary widely by state; no published South Dakota-specific rate is available in peer-reviewed literature as of this writing, but anecdotal reports from South Dakota lipid specialists suggest approvals are rare without strong documentation of statin intolerance and LDL above 190 mg/dL.

The South Dakota Department of Social Services publishes preferred drug list updates quarterly. Patients and clinicians can check the current formulary at the SD DSS Medicaid pharmacy page. Advocacy organizations including the FH Foundation provide template letters for Medicaid exception appeals that are directly relevant to South Dakota residents [3].

How Commercial Insurance Handles Prior Authorization in South Dakota

Most commercial plans in South Dakota require prior authorization (PA) for Praluent, and PA criteria typically mirror ACC/AHA guideline thresholds. Denials are common on first submission when documentation is incomplete.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with LDL-C levels persistently 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy who have ASCVD or HeFH, adding a PCSK9 inhibitor is reasonable" [4]. That language is almost directly transcribed into PA criteria by Blue Cross Blue Shield of South Dakota, Sanford Health Plan, and Wellmark, the three dominant commercial carriers in the state.

Standard PA documentation requirements across SD commercial plans include:

• A current fasting lipid panel showing LDL-C at or above the plan-specific threshold (often 70 mg/dL for ASCVD patients, 100 mg/dL for primary prevention)
• Evidence of at least two statin trials at maximally tolerated doses, one of which is typically required to be a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg)
• Documentation of ezetimibe use or a clinical reason for non-use
• A confirmed diagnosis of HeFH (by Dutch Lipid Clinic Network score or genetic testing) or established ASCVD

Step therapy is common. Several SD plans require a six-week trial of ezetimibe before approving a PCSK9 inhibitor even when the clinician has already prescribed it. Appeals that include peer-reviewed cardiovascular outcome data, specifically the ODYSSEY OUTCOMES trial, have a higher approval rate per clinical experience reported in lipid management literature [1].

Statin intolerance is a separate pathway. The National Lipid Association defines statin-associated muscle symptoms (SAMS) as a recognized clinical entity that, when documented with two failed statin trials, can justify bypassing step-therapy requirements [5]. Clinicians submitting PA requests for statin-intolerant SD patients should include a SAMS documentation checklist.

The Regeneron / Sanofi Savings Card for South Dakota Patients

Commercially insured South Dakota patients who meet eligibility criteria can pay as little as $0 per month through the Praluent Savings Card program run by Regeneron and Sanofi. Medicaid and Medicare patients are not eligible by federal law.

The savings card covers the gap between insurance copay and up to a defined program maximum per month. Patients enroll online at the Praluent manufacturer website and receive a card that works like a secondary payer at the pharmacy. Enrollment takes roughly five minutes and does not require income verification. The program has no fixed expiration announced for 2026, though manufacturer assistance programs are subject to change at the company's discretion.

Key eligibility criteria for the savings card:

• Must have commercial (private) insurance that covers Praluent
• Must be a U.S. resident, which includes South Dakota
• Must not be enrolled in any federal or state government insurance program, including Medicare Part D and South Dakota Medicaid

Patients who are uninsured are not eligible for the copay savings card but may qualify for the Praluent Patient Assistance Program (PAP), which provides free drug to patients meeting income thresholds. The PAP income threshold is typically set at or below 600% of the federal poverty level. A single adult in South Dakota earning under approximately $86,000 per year in 2026 may qualify. Applications go through the manufacturer or through NeedyMeds.org, which aggregates these programs [6].

Compounded Alirocumab in South Dakota: Legal Status and Practical Reality

Compounded alirocumab prepared by a licensed 503A pharmacy is legal in South Dakota and represents the lowest-cost access pathway for cash-pay patients who cannot use the manufacturer savings card.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed prescriber. Alirocumab is not on FDA's list of drug products that may not be compounded under 503A, meaning a South Dakota-licensed prescriber can write a prescription for compounded alirocumab and have it filled by a 503A-compliant pharmacy [7].

The legal framework does carry important caveats. A 503A pharmacy must prepare the compounded drug using bulk active pharmaceutical ingredients (APIs) from an FDA-registered facility. The compound must be prepared for a specific identified patient, not for office stock or general distribution. Quality control standards in 503A pharmacies vary more than in FDA-approved manufacturing, and the FDA does not evaluate compounded products for safety, efficacy, or quality before they reach patients [8].

From a clinical standpoint, compounded alirocumab formulations have not been tested in the large-scale outcome trials that established the cardiovascular benefit profile of brand-name Praluent. ODYSSEY OUTCOMES enrolled 18,924 patients across 57 countries using the FDA-approved Sanofi formulation specifically [1]. Whether compounded versions achieve equivalent pharmacokinetics depends on the API source, formulation, and storage conditions, none of which are standardized across 503A pharmacies.

Prescribers in South Dakota who consider compounded alirocumab for a patient should document the clinical rationale, typically financial hardship with inability to access brand-name drug through savings programs, and should confirm the pharmacy's 503A compliance status and API sourcing. The South Dakota Board of Pharmacy maintains a licensee lookup tool that can confirm a given pharmacy's active compounding license [9].

Telehealth Prescribing of Praluent in South Dakota

South Dakota permits telehealth prescribing of Praluent. Clinicians licensed in South Dakota can prescribe a Schedule-exempt drug like alirocumab via a synchronous audio-visual telehealth visit without requiring an in-person examination first, provided they establish a valid patient-provider relationship and document clinical necessity.

The South Dakota Telemedicine Act and subsequent guidance from the South Dakota Board of Medical and Osteopathic Examiners align with the general post-pandemic federal telehealth posture, which extended many pandemic-era flexibilities. Praluent is not a controlled substance, so the Ryan Haight Act restrictions that apply to buprenorphine or stimulants do not apply here. A cardiologist or internist practicing in Sioux Falls can evaluate a patient in a rural county via video and prescribe alirocumab the same day [10].

HealthRX clinicians licensed in South Dakota can complete a lipid assessment, review prior statin history, and issue a Praluent prescription or a compounded alirocumab prescription through a single telehealth visit. Lab results (a fasting lipid panel within the past 90 days) are typically required before the prescription is finalized. Patients in SD rural areas, where the nearest cardiologist may be 60 to 120 miles away, benefit most directly from this pathway.

The Clinical Evidence Behind the Prescription: Why Praluent Gets Prescribed

Alirocumab's cardiovascular benefit is established at the highest level of evidence. ODYSSEY OUTCOMES (N=18,924) randomized post-ACS patients to alirocumab 75 mg every two weeks (with dose adjustment to 150 mg if LDL remained above 50 mg/dL at eight weeks) versus placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, the primary composite endpoint of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization occurred in 9.5% of alirocumab patients versus 11.1% of placebo patients, a hazard ratio of 0.85 (95% CI 0.78 to 0.93, P<0.001) [1].

Absolute LDL reduction was substantial. Alirocumab lowered LDL-C by a mean of 54.7% from baseline compared with placebo at 48 months [1]. In the pre-specified subgroup with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was 3.4 percentage points, translating to a number needed to treat of 29 over 2.8 years to prevent one major cardiovascular event [1].

The ODYSSEY LONG TERM trial (N=2,341, 78-week follow-up) confirmed durable LDL reduction of 61% from baseline at week 24 and showed a nominal reduction in major cardiovascular events as a secondary endpoint, with a post-hoc analysis showing a 48% relative reduction in cardiovascular death, MI, stroke, and unstable angina versus placebo (P<0.001) [11].

For patients with HeFH specifically, the ODYSSEY FH I and FH II trials (combined N=735) demonstrated mean LDL-C reductions of 57.9% and 51.4% respectively versus placebo at week 24, with 59% to 72% of patients reaching LDL targets below 70 mg/dL [12].

The 2022 ACC/AHA cholesterol guideline places PCSK9 inhibitors in a Class IIa recommendation for patients with ASCVD whose LDL-C remains 70 mg/dL or above on maximally tolerated statin plus ezetimibe, and in a Class I recommendation for patients with HeFH and LDL-C above 100 mg/dL despite maximal statin and ezetimibe [4]. The National Lipid Association similarly supports alirocumab as a primary therapeutic option for statin-intolerant patients with very high cardiovascular risk [5].

Safety data across the ODYSSEY program are consistent. Injection-site reactions occurred in 7.2% of alirocumab patients versus 5.1% of placebo patients in ODYSSEY OUTCOMES, and were generally mild [1]. Neurocognitive adverse events were numerically slightly higher in alirocumab arms in early trials, but a dedicated cognitive substudy (ODYSSEY OUTCOMES Cognitive Study) found no difference in cognitive function between alirocumab and placebo groups at any time point [13].

Cost-Access Decision Framework for South Dakota Patients

Choosing between brand Praluent, the savings card, the PAP, and compounded alirocumab depends on four variables: insurance status, income, rural accessibility, and clinical urgency.

Step 1. Determine insurance status. Commercially insured patients should pursue PA first. If approved, the savings card can reduce copay to near zero. If denied, appeal with ODYSSEY OUTCOMES data and ACC/AHA 2022 guideline language [4].

Step 2. If uninsured and income-eligible, apply for PAP. The PAP can provide free brand-name Praluent and maintains the quality standards of the FDA-approved product. Processing typically takes two to four weeks, which matters for recently hospitalized ACS patients.

Step 3. If cash-pay and PAP-ineligible. Compounded alirocumab through a South Dakota-licensed 503A pharmacy is legal and may cost materially less than $580 per month, depending on the compounding pharmacy's pricing. Get pricing from at least two 503A-licensed pharmacies before committing.

Step 4. For rural SD patients with limited specialist access. Telehealth prescribing via a South Dakota-licensed clinician removes the geographic barrier. A fasting lipid panel at a local Quest or LabCorp draw site can be completed before the telehealth visit, allowing same-day prescription issuance.

Step 5. Monitor LDL at 4 to 8 weeks post-initiation. Whether on brand or compounded alirocumab, a repeat fasting lipid panel at four to eight weeks confirms therapeutic response. Target LDL-C for high-risk ASCVD patients is below 70 mg/dL per ACC/AHA 2022 [4]. For very high-risk patients (two or more major ASCVD events or one major event plus multiple high-risk conditions), the target is below 55 mg/dL [4].

Statin Alternatives and Combination Therapy Context

Alirocumab is rarely prescribed as a first-line agent. South Dakota clinicians typically reach for it after maximally tolerated statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) fails to bring LDL to goal, or after documented statin intolerance. The 2022 ACC/AHA guideline recommends adding ezetimibe 10 mg daily before escalating to a PCSK9 inhibitor, because ezetimibe adds roughly 18 to 25% additional LDL reduction at a generic cost of $10 to $20 per month [4].

Bempedoic acid (Nexletol) and the combination bempedoic acid plus ezetimibe (Nexlizet) are oral alternatives for statin-intolerant patients, approved by FDA in 2020 [14]. CLEAR Outcomes (N=13,970) showed bempedoic acid reduced the primary endpoint of major adverse cardiovascular events by 13% versus placebo in statin-intolerant patients at median follow-up of 40.6 months [15]. Bempedoic acid costs roughly $350 to $400 per month at SD pharmacies without insurance, positioning it between generic statin/ezetimibe combinations and alirocumab on the cost spectrum.

Inclisiran (Leqvio), a small interfering RNA PCSK9 inhibitor dosed just twice per year after two initial doses, received FDA approval in December 2021 [16]. Its dosing convenience is notable for rural South Dakota patients who face long travel distances for injectable drug access. List price is similar to alirocumab, and insurance coverage requirements are comparable.

What South Dakota Patients Should Bring to Their First Alirocumab Conversation

A productive initial conversation with a South Dakota prescriber about starting alirocumab requires specific documentation. Bring a fasting lipid panel from the past 90 days. Bring a medication history showing which statins you have taken, at what doses, and for how long. If you experienced muscle symptoms on statins, bring records of any CK (creatine kinase) levels drawn during those episodes. If you have a family history of premature cardiovascular disease or have been told you may have familial hypercholesterolemia, bring any genetic testing results or family history documentation you have.

Insurance card information matters too. The prescriber's office will need your commercial plan's phone number and member ID to initiate the PA process. If you are uninsured, bring proof of income (a recent pay stub or tax return) so the office can help determine PAP eligibility on the spot.

At a minimum, LDL-C above 70 mg/dL on maximally tolerated therapy in a patient with established ASCVD, or LDL-C above 100 mg/dL in a patient with HeFH, meets the clinical threshold most South Dakota payers recognize for PA approval [4]. An LDL-C result in your chart is the single most important document for starting this process.